From Medscape Gastroenterology

Medscape Coverage from the

International Liver Congress (ILC) 2017

April 19 - 23, 2017; Amsterdam, The Netherlands

April 19 - 23, 2017 Amsterdam, The Netherlands

ILC Navigating the Hep C Treatment and Cancer Risk Minefield Contradictory findings are driving disagreement over liver cancer risk after treatment with direct-acting antivirals for hepatitis C, and experts are shedding light on the way forward.
Medscape Medical News, June 2, 2017

Conference News

ILC Navigating the Hep C Treatment and Cancer Risk Minefield
Medscape Medical News, June 2, 2017
ILC Generic Direct-Acting Antivirals Effective in Hep C
Medscape Medical News, May 2, 2017
ILC Nivolumab Improves Sorafenib-Treated Liver Cancer
Medscape Medical News, April 28, 2017
ILC Fecal Transplant Safe for Hepatic Encephalopathy
Medscape Medical News, April 27, 2017
ILC New System Detects Cirrhosis in Fatty Liver Disease
Medscape Medical News, April 26, 2017

ILC Comparison Backs Bezafibrate for Biliary Cholangitis
Medscape Medical News, April 25, 2017
ILC Albumin Improves Survival in Decompensated Cirrhosis
Medscape Medical News, April 24, 2017
ILC Elevated Liver Cancer Risk for Older Hep B-Cleared Patients
Medscape Medical News, April 21, 2017
ILC Hep C Treatment Triumph Drives Broader Focus for ILC 2017
Medscape Medical News, April 11, 2017

Popular News from ILC 2016

Healthy Weight, but Expanding Waist Boosts Fatty Liver Risk A measuring tape might be an important addition to traditional calculations, like the numbers on the scale, to assess patients for fatty liver disease, investigators report.
Medscape Medical News, Apr 22, 2016
Slashing the Cost of Cure: Hep C Generics' First Data Shine Generic medications for hepatitis C, which are about 1% of the cost of brand-name drugs, pay back big, according to preliminary results from the REDEMPTION-1 trial.
Medscape Medical News, Apr 18, 2016
Liver Cancer Found in Hepatitis C Patients on New Antivirals For patients infected with chronic hepatitis C virus, there could be a downside to direct-acting antiviral therapy, which has been hailed as a cure.
Medscape Medical News, Apr 15, 2016

Medscape Gastroenterology© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Medscape Board at the Podium

Nancy Reau, MD
Rush University Medical Center, Chicago, Illinois
Presentation: Magellan-2: Safety and efficacy of glecaprevir/pibrentasvir in liver or renal transplant adults with chronic hepatitis C genotype 1-6 infection
Date: April 22, 2017

Previous Coverage

Related Resources

All material on this website is protected by copyright, Copyright © 1994-2019 by WebMD LLC. This website also contains material copyrighted by 3rd parties.